GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cangene Corporation (FRA:YGE) » Definitions » DeferredTaxAndRevenue

Cangene (FRA:YGE) DeferredTaxAndRevenue : €3.03 Mil (As of Oct. 2013)


View and export this data going back to . Start your Free Trial

What is Cangene DeferredTaxAndRevenue?

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Cangene's current deferred tax and revenue for the quarter that ended in Oct. 2013 was €3.03 Mil.

Cangene DeferredTaxAndRevenue Historical Data

The historical data trend for Cangene's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cangene DeferredTaxAndRevenue Chart

Cangene Annual Data
Trend Jul04 Jul05 Jul06 Jul07 Jul08 Jul09 Jul10 Jul11 Jul12 Jul13
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.87 2.64 2.25 1.53 2.91

Cangene Quarterly Data
Jan09 Apr09 Jul09 Oct09 Jan10 Apr10 Jul10 Oct10 Jan11 Apr11 Jul11 Oct11 Jan12 Apr12 Jul12 Oct12 Jan13 Apr13 Jul13 Oct13
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.56 1.89 1.95 2.91 3.03

Cangene DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of Cangene's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Cangene (FRA:YGE) Business Description

Traded in Other Exchanges
N/A
Address
Cangene Corporation is a fully integrated developer and manufacturer of immune therapeutics, primarily targeting infectious disease, hematology, transplantation and biodefense applications. The company manages its business and evaluate performance based on two operating segments: biopharmaceutical operations and contract services. Revenues are generated from product sales, and contract manufacturing and contract-R&D services.

Cangene (FRA:YGE) Headlines

No Headlines